Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04469777
Other study ID # 0304649
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date April 1, 2019
Est. completion date December 30, 2020

Study information

Verified date March 2021
Source Alexandria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.


Description:

Injury of the optic nerve or optic neuropathy is one of the most common causes of vision loss. This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 30, 2020
Est. primary completion date December 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases) Exclusion Criteria: - Patients with perforating ocular injuries were excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
erythropoietin
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Locations

Country Name City State
Egypt Alexandria Faculty of Medicine Alexandria

Sponsors (1)

Lead Sponsor Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of visual acuity Visual acuity using appropriate charts for assessment then convert into log of the minimum angle of resolution (logMAR) units to provide a numeric scale of visual acuity 3 months
Primary Flash visual-evoked potentials Flash VEP to detect amplitude reduction and latency in the optic nerve. 3 months
See also
  Status Clinical Trial Phase
Terminated NCT02982499 - Biomechanics of Optic Neuropathy
Recruiting NCT05543018 - Effect of Intraocular Tamponade on Visual Perception N/A
Completed NCT03318549 - BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases N/A
Terminated NCT03536559 - Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis Phase 2
Recruiting NCT06128720 - Hyperbaric Oxygen Therapy for Optic Neuropathies N/A
Withdrawn NCT01331616 - Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Early Phase 1
Not yet recruiting NCT05747781 - STReetlab Assessment Tool of Activities Daily Living in Glaucoma Patient N/A
Completed NCT01166594 - Use of Bevacizumab in Trabeculectomy Surgery Phase 4
Completed NCT03268681 - BIOtinidase Test In Optic-Neuropathy
Completed NCT02612571 - Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players N/A
Recruiting NCT03011541 - Stem Cell Ophthalmology Treatment Study II N/A
Completed NCT05853003 - Neuromuscular Ultrasonography Assessment of Optic Nerve in Systemic Lupus Eryhematosus
Enrolling by invitation NCT03760055 - Assessment of Visual Function With a Portable Brain-computer Interface
Recruiting NCT02638714 - Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells Phase 1/Phase 2